Polycystic ovary syndrome is associated with elevated plasma soluble CD40 ligand, a marker of coronary artery disease

Öktem, M.; Özçimen, Emel Ebru; Üçkuyu, Ayla; Esinler, İbrahim; Pamuk, Barış Önder; Bayraktar, Nilüfer; Kulaksızoğlu, Sevsen; Zeyneloglu, Hulusi Bulent

doi:10.1016/j.fertnstert.2008.03.039

Cited by 25 publications

(24 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Section: Discussionmentioning

confidence: 99%

“…sCD40 ligand is a trimeric, transmembrane protein present in platelets and is an important contributor to inflammatory processes that lead to thrombosis [18]. In women with PCOS, sCD40L levels were found to be significantly increased in Oktem et al [18] report. Then, the effects of OCS based treatment options (alone and combined spirinolactone treatments) on plasma soluble CD40L levels have been determined women with patients with PCOS [4].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Metformin plus oral contraceptive may decrease plasma sCD40 ligand in women with PCOS patients

Kebapçılar

Bilgir

et al. 2010

Gynecological Endocrinology

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Metformin plus oral contraceptive may decrease plasma sCD40 ligand in women with PCOS patients

Kebapçılar

Bilgir

et al. 2010

Gynecological Endocrinology

View full text Add to dashboard Cite

show abstract

“…According to our study, blood homocysteine levels were higher than normal in 13.0% of the women in the PCOS group and 23.3% of control group women, which was not significant. In contrast, two recent studies concluded that homocysteine is increased in women with polycystic ovary syndrome; [21,22] It is probably linked to elevated insulin level, insulin resistance and androgen levels [23]. On the other hand, Sohrabvand et al in Iranian population study showed that there was no significant difference in serum homocysteine between PCOS group and normal population; they concluded that it is probably related to race and higher administration of folic acid in infertile PCOS women [24].…”

Section: Discussionmentioning

confidence: 99%

A possible role for familial thrombophilia in women with polycystic ovarian syndrome

Moini¹,

Sarrafion

Ziaei

et al. 2011

Gynecological Endocrinology

View full text Add to dashboard Cite

show abstract

“…17-OH-progesterone tests were performed with RIA by using BioSource Europe S.A., Nivelles, Belgium. The Homeostasis Model Assessment Insulin Resistance index (HOMA-IR) was determined by using the following formula: fasting insulin (mU/L) × fasting glucose (mg/ dL)/22.5 (6). HOMA-IR value more than 2.5 was indicative of insulin resistance (7).…”

Section: Laboratory Measurementsmentioning

confidence: 99%

Evaluation of Polycystic Ovary Syndrome Patients with Strain Echocardiography

Aslan¹,

Aslan²,

Sade³

et al. 2015

IJWHR

View full text Add to dashboard Cite

IntroductionPolycystic Ovary Syndrome (PCOS) is a disorder of the reproductive system and is seen in 5 to 10% of the women in reproductive ages (1). Its main features are hyperandrogenism both clinical or biochemical and/or chronic oligo-anovulation and/or ultrasonographic appearance of the polycystic ovaries (2). There are many studies showing the relationship between PCOS and Cardiovascular Diseases (CVD). Insulin resistance, obesity, hypertension, hyperlipidemia, hypercoagulability, and endothelial dysfunction can be seen frequently in PCOS patients along with increased cardiovascular risks (3). Previously published data show that coronary atherosclerosis and increased carotid intima-media thickness can be observed in PCOS (4). The aim of our study was to determine the effects of metabolic factors on myocardial functions in PCOS patients, by measuring the strain (S) and strain rate (SR) as means of quantification of myocardial functions, which were first described by Heimdal et al. to define the global and regional myocardial dysfunction (5), and to identify the possible subclinical impairment of left ventricular myocardial function because of the metabolic components of PCOS. Materials and Methods Study populationThis study was carried out with 26 PCOS patients referred to the Obstetrics and Gynecology Clinic of Baskent University Hospital between December 2008 and September 2009 and 23 healthy female volunteers as control group. The PCOS patients were diagnosed in accordance with 2003 Rotterdam criteria (2). There were neither menstrual cycle abnormalities nor hyperandrogenism in the control group both clinically and biochemically. Clinical symptoms of hyperandrogenism were acne and/or hirsutism. A score higher than 7 based on the modified Ferriman-Gallwey Scale was noted as hirsutism. Any disease other than PCOS including hypertension, diabetes, thyroid function abnormalities, Cushing syndrome, asthma, and other auto-immune diseases, and all medical conditions which caused regular drug use were exclusion criteria for our study. All participants signed the informed consent before enrolling in our study. A physical examination with a detailed anamnesis including body weight and height were performed in all participants. Body Mass Index (BMI) was determined as body weight (kilograms) divided by height (meters) squared. AbstractObjectives: Polycystic Ovary Syndrome (PCOS) is characterized by several metabolic abnormalities that may lead to insulin resistance, diabetes, and atherosclerosis which are associated with chronic inflammatory processes and oxidative stress. Due to this fact PCOS patients are at increased risk of cardiovascular diseases. We used echocardiographic quantification tools to detect subclinical changes in myocardial functions. Materials and Methods:Echocardiographic, hormonal and metabolic measurements were performed in twenty-six women with PCOS and twenty-three healthy volunteers. The age of the attendants ranged between 20 and 31 years. PCOS was diagnosed by using the Rotterdam criteria. ...

show abstract

Polycystic ovary syndrome is associated with elevated plasma soluble CD40 ligand, a marker of coronary artery disease

Cited by 25 publications

References 35 publications

Metformin plus oral contraceptive may decrease plasma sCD40 ligand in women with PCOS patients

Metformin plus oral contraceptive may decrease plasma sCD40 ligand in women with PCOS patients

A possible role for familial thrombophilia in women with polycystic ovarian syndrome

Evaluation of Polycystic Ovary Syndrome Patients with Strain Echocardiography

Contact Info

Product

Resources

About